MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.22
-0.30
-5.43%
Opening 15:53 01/27 EST
OPEN
5.63
PREV CLOSE
5.52
HIGH
5.63
LOW
5.05
VOLUME
96.87K
TURNOVER
--
52 WEEK HIGH
43.21
52 WEEK LOW
4.740
MARKET CAP
25.57M
P/E (TTM)
-0.7658
1D
5D
1M
3M
1Y
5Y
BRIEF-Aptevo Therapeutics - Fuad El-Hibri, Chairman Of Board, Notified Co Of His Retirement, Resignation As A Director Of Co, Effective April 1, 2022
reuters.com · 6d ago
Aptevo Therapeutics Board Chairman Fuad El-Hibri to retire
Aptevo Therapeutics (NASDAQ:APVO) has announced the retirement of Fuad El-Hibri, the founding Chairman of the company's Board of Directors, effective April 1, 2022. Aptevo went public on the Nasdaq in
Seekingalpha · 6d ago
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
, to Assume Chairmanship, Effective April 1, 2022SEATTLE, WA / ACCESSWIRE / January 21, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeuti...
ACCESSWIRE · 6d ago
Aptevo Therapeutics' Board Chair to Retire, Successor Named
MT Newswires · 6d ago
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication In Peer-Reviewed Journal, 'Nature Communication'
Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed
Benzinga · 12/15/2021 13:08
Aptevo Therapeutics On Monday Published 2 Poster Presentations Ahead Of American Society Of Hematology, 1 Poster For Cytokine Release Syndrome, 1 For Single Agent Anti-Neplastic Activity
https://aptevotherapeutics.gcs-web.com/static-files/893a3758-337a-4f06-824a-64da0cebf9dd https://aptevotherapeutics.gcs-web.com/static-files/638ab153-b1ff-49ee-b4b3-b1bed667bf73
https://aptevotherapeutics.gcs-web.com/static-files/638ab153-b1ff-49ee-b4b3-b1bed667bf73 · 12/14/2021 21:45
LCID, EDIT and BLUE among pre market gainers
Arena Pharmaceuticals (NASDAQ:ARNA) +90% on acquisition by Pfizer. Foghorn Therapeutics (NASDAQ:FHTX) +38% after collaborating with Lilly in oncology medicines. BELLUS Health (NASDAQ:BLU) +36% on positive BLU-5937 data in mid-stage chronic cough study. Pet...
Seekingalpha · 12/13/2021 13:37
22 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday.
Benzinga · 12/13/2021 11:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APVO. Analyze the recent business situations of Aptevo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average APVO stock price target is 52.50 with a high estimate of 69.00 and a low estimate of 36.00.
High69.00
Average52.50
Low36.00
Current 5.22
EPS
Actual
Estimate
-1.11-0.310.501.31
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 57
Institutional Holdings: 5.72M
% Owned: 116.85%
Shares Outstanding: 4.90M
TypeInstitutionsShares
Increased
6
5.31K
New
6
631.02K
Decreased
3
16.55K
Sold Out
8
411.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About APVO
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific and multi-specific antibody candidates that are capable for the human immune system against cancer cells. The Company's lead product candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using the ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using the ADAPTIR-FLEX modular protein technology platform. APVO436 is a recombinant, bispecific T-cell engaging antibody candidate that is designed to target CD123, CD3 and redirect T-cell cytotoxicity to the tumor.

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.